{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:36:45Z","timestamp":1793853405888,"version":"4.6.1"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T00:00:00Z","timestamp":1670544000000},"content-version":"vor","delay-in-days":1134,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T00:00:00Z","timestamp":1565740800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,11,1]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Weekly adalimumab (Humira\u00ae) is approved for the treatment of hidradenitis suppurativa (HS) based on the 12-week placebo-controlled periods of the two phase III PIONEER trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Using PIONEER integrated trial results, we aimed to evaluate the optimal medium-term adalimumab maintenance dosing strategy for moderate-to-severe HS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Each trial had two double-blind periods; 12-week Period A and 24-week Period B. Patients randomized to adalimumab 40 mg every week (ADAew) (Period A), were rerandomized in Period B to ADAew (ADAew\/ew), ADA every other week (ADAew\/eow), or placebo (ADAew\/pbo). Placebo-randomized patients were reassigned in Period B to ADAew (PIONEER I) or placebo (PIONEER II). The primary outcome was HS Clinical Response (HiSCR). Patients who lost response during Period B were discontinued from the study and offered an option to enter the open-label extension (OLE) to receive ADAew. Results are reported across the two study periods, and data were combined from the two study periods and the OLE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>For week-12 HiSCR achievers, the HiSCR week-36 rate was 48\u00b71% (ADAew\/ew) vs. 46\u00b72% (ADAew\/eow) and 32\u00b71% (ADAew\/pbo). Combining (post hoc) these patients with week-12 partial responders further differentiated outcomes in Period B (ADAew\/ew 55\u00b77% vs. ADAew\/eow 40\u00b70% and ADAew\/pbo 30\u00b71%). Period-B adverse-event rates were ADAew\/ew 59\u00b76% vs. ADAew\/eow 57\u00b74% and ADAew\/pbo 65\u00b70%. One patient (ADAew\/ew) reported a serious infection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Weekly adalimumab treatment, effective throughout 36 weeks, was the optimal maintenance medium-term dosing regimen for this population. At least partial response after 12 weeks with continued weekly dosing had better outcomes than dose reduction or interruption. Patients who do not show at least a partial response to weekly adalimumab by week 12 are unlikely to benefit from continued therapy. No new safety risks were identified.<\/jats:p>\n                    <jats:p>What's already known about this topic?<\/jats:p>\n                    <jats:p>Hidradenitis suppurativa (HS) is a chronic inflammatory disease, commonly misinterpreted as an infection and treated with long-term antibiotic regimens or surgical incisions. Based on the chronicity of HS and the lack of evidence for efficacious and safe long-term HS treatments, it is important to evaluate medium- to long-term therapies for HS. Weekly adalimumab (Humira\u00ae) is approved for the treatment of moderate-to-severe HS based on the two phase III PIONEER trials.<\/jats:p>\n                    <jats:p>What does this study add?<\/jats:p>\n                    <jats:p>This study pooled data from the two PIONEER trials, providing a more robust assessment of outcomes. After at least partial treatment success with weekly adalimumab short-term therapy (12 weeks), continuing weekly dosing during the subsequent 24 weeks had better outcomes than dose reduction or treatment interruption. Patients who do not show at least a partial response to weekly adalimumab by week 12 are unlikely to benefit from continued therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bjd.17919","type":"journal-article","created":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T17:45:36Z","timestamp":1553708736000},"page":"967-975","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials"],"prefix":"10.1093","volume":"181","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0712-2540","authenticated-orcid":false,"given":"G.B.E.","family":"Jemec","sequence":"first","affiliation":[{"name":"Department of Dermatology Zealand University Hospital Health Sciences Faculty University of Copenhagen Roskilde Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.M.","family":"Okun","sequence":"additional","affiliation":[{"name":"Fort HealthCare Fort Atkinson WI U.S.A"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.B.","family":"Forman","sequence":"additional","affiliation":[{"name":"Forward Clinical Trials Tampa FL U.S.A"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.P.F.","family":"Gulliver","sequence":"additional","affiliation":[{"name":"Memorial University of Newfoundland St John's Newfoundland and Labrador Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.P.","family":"Prens","sequence":"additional","affiliation":[{"name":"Erasmus University Medical Center Rotterdam the Netherlands"},{"name":"CHU de Reims H\u00f4pital Robert Debr\u00e9, Service de Dermatologie Reims Cedex France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9539-0712","authenticated-orcid":false,"given":"U.","family":"Mrowietz","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology, and Allergology University Medical Center Schleswig-Holstein Campus Kiel Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6892-6286","authenticated-orcid":false,"given":"A.W.","family":"Armstrong","sequence":"additional","affiliation":[{"name":"Keck School of Medicine University of Southern California Los Angeles CA U.S.A"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Geng","sequence":"additional","affiliation":[{"name":"AbbVie Inc. North Chicago IL U.S.A"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Gu","sequence":"additional","affiliation":[{"name":"AbbVie Inc. North Chicago IL U.S.A"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.A.","family":"Williams","sequence":"additional","affiliation":[{"name":"AbbVie Inc. North Chicago IL U.S.A"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.D.","family":"Teixeira","sequence":"additional","affiliation":[{"name":"AbbVie Inc. North Chicago IL U.S.A"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.B.","family":"Kimball","sequence":"additional","affiliation":[{"name":"Harvard Medical School and Beth Israel Deaconess Hospital Boston MA U.S.A"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,11,1]]},"reference":[{"key":"2023083116104987000_bjd17919-bib-0001","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/j.1468-3083.2009.03356.x","article-title":"Hidradenitis suppurativa","volume":"23","author":"Revuz","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023083116104987000_bjd17919-bib-0002","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1056\/NEJMcp1014163","article-title":"Clinical practice. Hidradenitis suppurativa","volume":"366","author":"Jemec","year":"2012","journal-title":"N Engl J Med"},{"key":"2023083116104987000_bjd17919-bib-0003","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.jaad.2014.09.012","article-title":"Hidradenitis suppurativa is a systemic disease with substantial comorbidity burden: a chart-verified case-control analysis","volume":"71","author":"Shlyankevich","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"2023083116104987000_bjd17919-bib-0004","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1159\/000443878","article-title":"The ABC of hidradenitis suppurativa: a validated glossary on how to name lesions","volume":"232","author":"Lipsker","year":"2016","journal-title":"Dermatology"},{"key":"2023083116104987000_bjd17919-bib-0005","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1600-0625.2008.00712.x","article-title":"What causes hidradenitis suppurativa?","volume":"17","author":"Kurzen","year":"2008","journal-title":"Exp Dermatol"},{"key":"2023083116104987000_bjd17919-bib-0006","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.1365-2230.1996.tb00145.x","article-title":"Hidradenitis suppurativa\u2013characteristics and consequences","volume":"21","author":"Jemec","year":"1996","journal-title":"Clin Exp Dermatol"},{"key":"2023083116104987000_bjd17919-bib-0007","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1046\/j.1365-2133.2001.04137.x","article-title":"Morbidity in patients with hidradenitis suppurativa","volume":"144","author":"von der Werth","year":"2001","journal-title":"Br J Dermatol"},{"key":"2023083116104987000_bjd17919-bib-0008","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1001\/jamadermatol.2017.0904","article-title":"The follicular skin microbiome in patients with hidradenitis suppurativa and healthy controls","volume":"153","author":"Ring","year":"2017","journal-title":"JAMA Dermatol"},{"key":"2023083116104987000_bjd17919-bib-0009","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/jdv.12966","article-title":"European S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa","volume":"29","author":"Zouboulis","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023083116104987000_bjd17919-bib-0010","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/exd.12830","article-title":"Deciphering the microbiology of hidradenitis suppurativa: a step forward towards understanding an enigmatic inflammatory skin disease","volume":"24","author":"Delage","year":"2015","journal-title":"Exp Dermatol"},{"key":"2023083116104987000_bjd17919-bib-0011","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/exd.12793","article-title":"The bacteriology of hidradenitis suppurativa: a systematic review","volume":"24","author":"Ring","year":"2015","journal-title":"Exp Dermatol"},{"key":"2023083116104987000_bjd17919-bib-0012","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000446812","article-title":"Microbial profile and antimicrobial susceptibility of bacteria found in inflammatory hidradenitis suppurativa lesions","volume":"29","author":"Hessam","year":"2016","journal-title":"Skin Pharmacol Physiol"},{"key":"2023083116104987000_bjd17919-bib-0013","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.det.2015.08.010","article-title":"The microbiology of hidradenitis suppurativa","volume":"34","author":"Ring","year":"2016","journal-title":"Dermatol Clin"},{"key":"2023083116104987000_bjd17919-bib-0014","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jaad.2016.08.001","article-title":"Patterns of antimicrobial resistance in lesions of hidradenitis suppurativa","volume":"76","author":"Fischer","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2023083116104987000_bjd17919-bib-0015","doi-asserted-by":"crossref","first-page":"208","DOI":"10.2340\/00015555-2503","article-title":"Normal skin microbiota is altered in pre-clinical hidradenitis suppurativa","volume":"97","author":"Ring","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"2023083116104987000_bjd17919-bib-0016","doi-asserted-by":"crossref","first-page":"846","DOI":"10.7326\/0003-4819-157-12-201212180-00004","article-title":"Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial","volume":"157","author":"Kimball","year":"2012","journal-title":"Ann Intern Med"},{"key":"2023083116104987000_bjd17919-bib-0017","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa","volume":"375","author":"Kimball","year":"2016","journal-title":"N Engl J Med"},{"key":"2023083116104987000_bjd17919-bib-0018","first-page":"623","volume-title":"Dermatologic Surgery: Principles and Practice","author":"Hurley","year":"1996","edition":"2nd edn"},{"key":"2023083116104987000_bjd17919-bib-0019","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1111\/bjd.13270","article-title":"Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment","volume":"171","author":"Kimball","year":"2014","journal-title":"Br J Dermatol"},{"key":"2023083116104987000_bjd17919-bib-0020","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000431175","article-title":"Hidradenitis suppurativa\/acne inversa: criteria for diagnosis, severity assessment, classification and disease evaluation","volume":"231","author":"Zouboulis","year":"2015","journal-title":"Dermatology"},{"key":"2023083116104987000_bjd17919-bib-0021","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/sim.6343","article-title":"A PRIM approach to predictive-signature development for patient stratification","volume":"34","author":"Chen","year":"2015","journal-title":"Stat Med"},{"key":"2023083116104987000_bjd17919-bib-0022","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.lungcan.2015.09.011","article-title":"Plasma biomarker signature associated with improved survival in advanced non-small cell lung cancer patients on linifanib","volume":"90","author":"McKeegan","year":"2015","journal-title":"Lung Cancer"},{"key":"2023083116104987000_bjd17919-bib-0023","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/bjd.13090","article-title":"Risk factors, clinical course and long-term prognosis in hidradenitis suppurativa: a cross-sectional study","volume":"171","author":"Kromann","year":"2014","journal-title":"Br J Dermatol"},{"key":"2023083116104987000_bjd17919-bib-0024","volume-title":"Antimicrobial resistance surveillance in Europe 2015. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net)","author":"European Centre for Disease Prevention and Control"},{"key":"2023083116104987000_bjd17919-bib-0025","volume-title":"Global Action Plan on Antimicrobial Resistance, 2015","author":"World Health Organization"},{"key":"2023083116104987000_bjd17919-bib-0026","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1396-0296.2004.04007.x","article-title":"Hidradenitis suppurativa: a review","volume":"17","author":"Wiseman","year":"2004","journal-title":"Dermatol Ther"},{"key":"2023083116104987000_bjd17919-bib-0027","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.det.2010.07.003","article-title":"Hidradenitis suppurativa","volume":"28","author":"Danby","year":"2010","journal-title":"Dermatol Clin"},{"issue":"Suppl. 2","key":"2023083116104987000_bjd17919-bib-0028","doi-asserted-by":"crossref","first-page":"S161","DOI":"10.1016\/j.jid.2016.06.023","article-title":"Therapeutic response guided dosing strategy to optimize long-term adalimumab treatment in patients with hidradenitis suppurativa: integrated results from the PIONEER phase 3 trials","volume":"136","author":"Gulliver","year":"2016","journal-title":"J Invest Dermatol"},{"key":"2023083116104987000_bjd17919-bib-0029","volume-title":"BMI Classification","author":"World Health Organization"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjd.17919","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjd.17919","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjd.17919","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/181\/5\/967\/51317249\/bjd0967.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/181\/5\/967\/51317249\/bjd0967.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T12:28:25Z","timestamp":1693484905000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/181\/5\/967\/6602200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,1]]},"references-count":29,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,11,1]]},"published-print":{"date-parts":[[2019,11,1]]}},"URL":"https:\/\/doi.org\/10.1111\/bjd.17919","relation":{},"ISSN":["1365-2133","0007-0963"],"issn-type":[{"value":"1365-2133","type":"electronic"},{"value":"0007-0963","type":"print"}],"subject":[],"published-other":{"date-parts":[[2019,11,1]]},"published":{"date-parts":[[2019,11,1]]},"assertion":[{"value":"2019-03-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}